Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 8/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | DRD3 | P35462 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | G6PD | P11413 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | JAK1 | P23458 | 2/20 | 0.32 |
| ▸ | TYK2 | P29597 | 2/20 | 0.32 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2959947 | 0.91 | MAP4K4 (0.39) | MAP4K4EGFRKDRPIK3CADRD2 | |
| Formic Acid SCHEMBL30455236 | 0.82 | EGFR (0.35) | MAP4K4EGFRKDRPIK3CADRD2 | |
| SCHEMBL9934420 | 0.77 | MAP4K4 (0.44) | MAP4K4PIK3CADRD2DRD3DRD4 | |
| SCHEMBL3485186 | 0.76 | DRD3 (0.47) | DRD2DRD3LMNAKDM4EMEN1 | |
| SCHEMBL24548207 | 0.73 | MAP4K4 (0.44) | MAP4K4EGFRKDRPIK3CADRD2 | |
| SCHEMBL30489874 | 0.73 | MAP4K4 (0.53) | MAP4K4EGFRPIK3CADRD2DRD3 | |
| SCHEMBL5019489 | 0.73 | MAP4K4 (0.44) | MAP4K4EGFRKDRPIK3CADRD2 | |
| SCHEMBL25776599 | 0.73 | MAP4K4 (0.44) | MAP4K4PIK3CADRD2DRD3KDM4E | |
| SCHEMBL9934294 | 0.73 | MAP4K4 (0.39) | MAP4K4PIK3CADRD2DRD3DRD4 | |
| SCHEMBL867042 | 0.70 | MAP4K4 (0.60) | MAP4K4EGFRKDRPIK3CAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4051680-B1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12391697-B2 | Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2025-08-19 | — | — | US | disclosed |
| WO-2025106362-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230025892-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230025892-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2023-01-26 | — | — | US | disclosed |
| US-11548890-B1 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4051680-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| US-11078201-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20210078996-A1 | HPK1 ANTAGONISTS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
| EP-3042905-B1 | PROTEIN KINASE INHIBITOR CONTAINING PYRROLOPYRIDAZINE DERIVATIVE | WELLMARKER BIO CO LTD (KR) | 2020-06-17 | — | — | EP | disclosed |
| US-9815840-B2 | Protein kinase inhibitor containing pyrrolopyridazine derivative | THE ASAN FOUNDATION (KR) | 2017-11-14 | — | — | US | disclosed |
| US-20160207931-A1 | PROTEIN KINASE INHIBITOR CONTAINING PYRROLOPYRIDAZINE DERIVATIVE | CJ HEALTHCARE CORPORATION (KR) | 2016-07-21 | — | — | US | disclosed |
| EP-3042905-A1 | PROTEIN KINASE INHIBITOR CONTAINING PYRROLOPYRIDAZINE DERIVATIVE | CJ Healthcare Corporation (KR) | 2016-07-13 | — | — | EP | disclosed |
| CN-105683191-A | Protein kinase inhibitor containing pyrrolopyridazine derivative | CJ医药健康株式会社 | 2016-06-15 | — | — | CN | disclosed |
| EP-2459557-B1 | CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2013-09-18 | — | — | EP | disclosed |
| US-8415336-B2 | Cyclic (aza)indolizinecarboxamides, their preparation and their use as pharmaceuticals | SANOFI (FR) | 2013-04-09 | — | — | US | disclosed |
| US-20120232081-A1 | CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-09-13 | — | — | US | disclosed |
| EP-2459557-A1 | CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548890-B1 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | MAP4K4 145/4885EGFR 4399/4885KDR 4387/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | MAP4K4 145/4885EGFR 4399/4885KDR 4387/4885 |
| US-20230025892-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, CDK1, CDK2 | MAP4K4 212/4885EGFR 968/4885KDR 487/4885 |
| US-20160207931-A1 | PROTEIN KINASE INHIBITOR CONTAINING PYRROLOPYRIDAZINE DERIVATIVE | MAPKAPK5, MAP3K5, PRKCA | MAP4K4 25/4885EGFR 1420/4885KDR 1931/4885 |
| US-20120232081-A1 | CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | REN, ACE, PM20D2 | MAP4K4 1606/4885EGFR 2621/4885KDR 1262/4885 |
| US-20210078996-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | MAP4K4 145/4885EGFR 4399/4885KDR 4387/4885 |
| US-12391697-B2 | Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase | ABL1, CDK1, CDK2 | MAP4K4 212/4885EGFR 968/4885KDR 487/4885 |
| US-11078201-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists | HIPK1, PDXK, IP6K1 | MAP4K4 149/4885EGFR 4733/4885KDR 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.